GB262 / Edding Genor Group - LARVOL DELTA

[VIRTUAL] Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy (AACR 2021) - "GB262 is the first bispecific antibody that not only releases cancer repression on T-cell activation, but also releases cancer repression on CDC. By conjugating to a toxin, GB262 could serve as an ADC to target multiple cancer cells. GB262 has potential to serve as a novel therapy for many cancers."

IO biomarker • Late-breaking abstract • Oncology